About Viking Therapeutics, Inc. - Common Stock (VKTX)
Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company is engaged in advancing a portfolio of drug candidates aimed at addressing diseases with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH) and obesity. Viking’s approach leverages proprietary drug development technologies to design and optimize novel therapeutic compounds, with an emphasis on safety and efficacy. Through its research and clinical trials, the company aims to bring transformative treatments to market that can improve patient outcomes and enhance quality of life. Read More
NEW YORK — In a dramatic shift that has redefined the market landscape of 2025, small-cap stocks have surged to historic levels, signaling what many analysts are calling the "Great Rotation." On December 18, 2025, the Russell 2000 index—the primary benchmark for smaller American companies—closed at an all-time high
As of mid-December 2025, the long-awaited "Great Rotation" in the financial markets has shifted from a theoretical prediction to a dominant reality. For the better part of the last three years, small-cap stocks have lived in the shadow of the "Magnificent Seven" tech titans, but the tide has turned. Today,
Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area and the recent positive momentum after major clinical trial developments.
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.
Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61.
Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.
